RUTHERFORD, N.J., Oct. 28, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), a diagnostics company focused on developing genomic-based, oncology tests and services, today announced the closing of its previously announced public offering of 3,286,700 shares of its common stock (including 428,700 shares that were offered and sold by Cancer Genetics pursuant to the exercise in full of the underwriters’ over-allotment option) at a price to the public of $14.00 per share. The gross proceeds to Cancer Genetics from the offering were $46 million, before underwriting discounts and commissions and other offering expenses payable by Cancer Genetics.
Help employers find you! Check out all the jobs and post your resume.
